Uzbekistan and Egypt have agreed to collaborate on the production of Daclatasvir and Sofosbuvir, key medications for treating hepatitis C, for the domestic market.

The agreement was reached during an online meeting attended by representatives from Egyptian companies ACDIMA and Dentafill Plus, along with Uzbekistan’s Pharmaceutical Industry Development Agency, The Caspian Post reports via Uzbek media.

Under the project, production technologies will be gradually implemented in Uzbekistan, Egyptian experts will provide guidance, local personnel will be trained, and manufacturing facilities adapted for the new production lines.

Participants also explored opportunities to localize over 1,000 types of medicines and discussed prospects for producing insulin domestically.

Officials note that the partnership will strengthen Uzbekistan’s pharmaceutical industry, reduce reliance on imports, and foster industrial cooperation between the two countries, creating a model for regional pharmaceutical development.